Praxis Precision Medicines (PRAX) grants RSUs and stock options to director

Rhea-AI Filing Summary

Praxis Precision Medicines director Jeffrey B. Kindler reported new equity awards. On February 6, 2026, he received 688 restricted stock units that vest in two equal annual installments on the first two anniversaries of January 8, 2026.

He was also granted 478 restricted stock units that vest in a single installment on the earlier of June 26, 2026 or the company’s 2026 annual shareholder meeting. Following these grants, he directly holds 1,166 shares of common stock tied to these awards.

In addition, Kindler received a stock option for 224 shares of common stock with a stated exercise price of $319.57 per share, vesting in equal monthly installments from February 26, 2026 through the earlier of June 26, 2026 or the 2026 annual meeting.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KINDLER JEFFREY B

(Last) (First) (Middle)

C/O PRAXIS PRECISION MEDICINES, INC.

99 HIGH STREET, 30TH FLOOR

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/06/2026		A(1)		688	A	$0	688	D
Common Stock	02/06/2026		A(2)		478	A	$0	1,166	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$319.57	02/06/2026		A		224		(3)	02/06/2036	Common Stock	224	$0	224	D

Explanation of Responses:

1. Mr. Kindler was awarded 688 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in two equal annual installments occurring on the first two anniversaries of January 8, 2026. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

2. Mr. Kindler was awarded 478 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 26, 2026 or (ii) the date of the Issuer's 2026 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

3. The shares subject to this option shall vest in equal monthly installments occurring on the 26th day of each month, with the first such installment occurring on February 26, 2026 and the final such installment occurring on the earlier of (i) June 26, 2026 or (ii) the date of the Issuer's 2026 annual meeting of stockholders.

Remarks:

	/s/ Alex Nemiroff, as Attorney-in-Fact	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Praxis Precision Medicines (PRAX) disclose for Jeffrey B. Kindler?

Praxis Precision Medicines disclosed that director Jeffrey B. Kindler received new equity compensation awards. These include restricted stock units and a stock option, all granted on February 6, 2026, reflecting routine director compensation rather than an open‑market purchase or sale of existing shares.

How many restricted stock units did Jeffrey B. Kindler receive from PRAX and how do they vest?

Jeffrey B. Kindler received 688 restricted stock units plus 478 restricted stock units. The 688 units vest in two equal annual installments starting on January 8, 2026 anniversaries, while the 478 units vest in a single installment tied to June 26, 2026 or the 2026 shareholder meeting.

What are the vesting terms of the 478 PRAX restricted stock units granted to Jeffrey Kindler?

The 478 restricted stock units vest in one installment. Vesting occurs on the earlier of June 26, 2026 or the date of Praxis Precision Medicines’ 2026 annual meeting of stockholders, after which each unit can be settled in one share of common stock.

What stock option did Jeffrey B. Kindler receive from Praxis Precision Medicines?

Jeffrey B. Kindler received a stock option covering 224 shares of Praxis common stock at an exercise price of $319.57 per share. The option vests in equal monthly installments beginning February 26, 2026 through the earlier of June 26, 2026 or the 2026 annual meeting.

How many Praxis Precision Medicines shares does Jeffrey Kindler beneficially own after these grants?

After the reported transactions, Jeffrey B. Kindler beneficially owns 1,166 shares of Praxis Precision Medicines common stock related to the restricted stock unit grants. This figure comes directly from the Form 4 and reflects his direct ownership following the February 6, 2026 awards.

Do the PRAX restricted stock units reported for Jeffrey Kindler settle in cash or shares?

The restricted stock units granted to Jeffrey Kindler settle only in shares. Each unit represents a contingent right to receive one share of Praxis Precision Medicines common stock, and the disclosure states they may be settled only by delivering shares under SEC guidance.